Recent Updates
Recently added Catalysts
SYRE Neutral Sentiment

Spyre Therapeutics to Participate in Upcoming Investor Conference Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic...

Key Takeaway: Spyre Therapeutics, Inc. (NASDAQ: SYRE) will participate in an upcoming investor conference, where they plan to showcase their advancements in antibody engineering and therapeutic development. A replay of the webcast will be accessible on their investor events website for 90 days after the event. The company's activities remain focused on progressive biotechnological innovations in the clinical stage. Details about the specific presentations or research updates at the conference have not been disclosed.
Price reaction · baseline $29.08 (2024-09-09 close) · hit after-hours · clean, no other SYRE news in the window
day 0 close · peak
-3.1%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+249%
120-day peak, hindsight
Typical move
3.2%
average across 3 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
Co-ArgI-PEG modified human arginase I
Phase 2 · Acute Myeloid Leukemia

Full Press Release Details

A webcast replay will be available on the Spyre investor events website for 90 days following the event.
About Spyre Therapeutics
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
SOURCE Spyre Therapeutics, Inc.

21 %

Frequently Asked Questions

Where can I find the webcast replay for Spyre events?

The webcast replay will be available on the Spyre investor events website.

How long will the webcast replay be available?

The replay will be accessible for 90 days after the event.

Where can I follow Spyre Therapeutics online?

You can follow Spyre Therapeutics on social media @spyretx and LinkedIn.

Who is the source of the information on Spyre Therapeutics?

The information is sourced from Spyre Therapeutics, Inc.

Last updated: Sep 10, 2024